Mycobacterium tuberculosis metabolism

Cold Spring Harbor Perspectives in Medicine

Volumn 5, Issue 4, 2015, Pages

  Warner, Digby F ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

TUBERCULOSTATIC AGENT;

ARTICLE; AUXOTROPHY; BACILLUS; BACTERIAL GROWTH; BACTERIAL METABOLISM; BACTERIAL TRANSMISSION; CARBON METABOLISM; DRUG EFFICACY; DRUG METABOLISM; DRUG RESPONSE; DRUG TARGETING; EARLY INTERVENTION; ENVIRONMENTAL FACTOR; EVOLUTIONARY ADAPTATION; GENOMICS; GLUCONEOGENESIS; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; IN VIVO STUDY; INTRACELLULAR SPACE; METABOLIC CAPACITY; METABOLOMICS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OUTCOME ASSESSMENT; SYSTEMS BIOLOGY; TUBERCULOSIS; DRUG DEVELOPMENT; IMMUNOLOGY; METABOLISM; MICROBIOLOGY;

BACILLI (CLASS); BACILLUS (BACTERIUM); MYCOBACTERIUM TUBERCULOSIS;

ANTITUBERCULAR AGENTS; DRUG DISCOVERY; HOST-PATHOGEN INTERACTIONS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 84926311587     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a021121     Document Type: Article

References (189)

1. Abrahams GL, Kumar A, Savvi S, Hung AW, Wen S, Abell C, Barry CE 3rd, Sherman DR, Boshoff HI, Mizrahi V. 2012. Pathway-selective sensitization of Mycobacterium tuberculosis for target-based whole-cell screening. Chem Biol 19: 844–854.
2. Agarwal N, Lamichhane G, Gupta R, Nolan S, Bishai WR. 2009. Cyclic AMP intoxication of macrophages by a Mycobacterium tuberculosis adenylate cyclase. Nature 460: 98–102.
3. Alderwick LJ, Harrison J, Lloyd GS, Birch HL. 2014. The mycobacterial cell wall—Peptidoglycan and arabinogalactan. Cold Spring Harb Perspect Med doi: 10.1101/ cshperspect.a021113.
4. Arnvig KB, Comas I, Thomson NR, Houghton J, Boshoff HI, Croucher NJ, Rose G, Perkins TT, Parkhill J, Dougan G, et al. 2011. Sequence-based analysis uncovers an abundance of non-coding RNA in the total transcrip tome of Mycobacterium tuberculosis. PLoS Pathog 7: e1002342.
5. Bacon J, Alderwick LJ, Allnutt JA, Gabasova E, Watson R, Hatch KA, Clark SO, Jeeves RE, Marriott A, Rayner E, et al. 2014. Non-replicating Mycobacterium tuberculosis elicits a reduced infectivity profile with corresponding modifications to the cell wall and extracellular matrix. PLoS ONE 9: e87329.
6. Baek SH, Li AH, Sassetti CM. 2011. Metabolic regulation of mycobacterial growth and antibiotic sensitivity. PLoS Biol 9: e1001065.
7. Barrios-Payan J, Saqui-Salces M, Jeyanathan M, Alcantara Vazquez A, Castanon-Arreola M, Rook G, HernandezPando R. 2012. Extrapulmonary locations of Mycobacterium tuberculosis DNA during latent infection. J Infect Dis 206: 1194–1205.
8. Barry CE 3rd, Boshoff HI, Dartois V, Dick T, Ehrt S, Flynn J, Schnappinger D, Wilkinson RJ, Young D. 2009. The spectrum of latent tuberculosis: Rethinking the biology and intervention strategies. Nat Rev Microbiol 7: 845–855.
9. Baruch M, Belotserkovsky I, Hertzog BB, Ravins M, Dov E, McIver KS, Le Breton YS, Zhou Y, Chen CY, Hanski E. 2014. An extracellular bacterial pathogen modulates host metabolism to regulate its own sensing and proliferation. Cell 156: 97–108.
10. Baughn AD, Garforth SJ, Vilcheze C, Jacobs WR Jr., 2009. An anaerobic-type a-ketoglutarate ferredoxin oxidoreductase completes the oxidative tricarboxylic acid cycle of Mycobacterium tuberculosis. PLoS Pathog 5: e1000662.
11. Behrends V, Ryall B, Zlosnik JE, Speert DP, Bundy JG, Williams HD. 2013. Metabolic adaptations of Pseudomonas aeruginosa during cystic fibrosis chronic lung infections. Environ Microbiol 15: 398–408.
12. Berg IA, Filatova LV, Ivanovsky RN. 2002. Inhibition of acetate and propionate assimilation by itaconate via propionyl-CoA carboxylase in isocitrate lyase-negative purple bacterium Rhodospirillum rubrum. FEMS microbiology letters 216: 49–54.
13. Beste DJ, McFadden J. 2010. System-level strategies for studying the metabolism of Mycobacterium tuberculosis. Mol Biosyst 6: 2363–2372.
14. Beste DJ, Peters J, Hooper T, Avignone-Rossa C, Bushell ME, McFadden J. 2005. Compiling a molecular inventory for Mycobacterium bovis BCG at two growth rates: Evidence for growth rate-mediated regulation of ribosome biosynthesis and lipid metabolism. J Bacteriol 187: 1677–1684.
15. 13C metabolic flux analysis identifies an unusual route for pyruvate dissimilation in mycobacteria which requires isocitrate lyase and carbon dioxide fixation. PLoS Pathog 7: e1002091.
16. 13C-flux spectral analysis of host-pathogen metabolism reveals a mixed diet for intracellular Mycobacterium tuberculosis. Chem Biol 20: 1012–1021.
17. Bisson GP, Mehaffy C, Broeckling C, Prenni J, Rifat D, Lun DS, Burgos M, Weissman D, Karakousis PC, Dobos K. 2012. Upregulation of the phthiocerol dimycocerosate biosynthetic pathway by rifampin-resistant, rpoB mutant Mycobacterium tuberculosis. J Bacteriol 194: 6441–6452.
18. Blumenthal A, Trujillo C, Ehrt S, Schnappinger D. 2010. Simultaneous analysis of multiple Mycobacterium tuberculosis knockdown mutants in vitro and in vivo. PLoS ONE 5: e15667.
19. Bonde BK, Beste DJ, Laing E, Kierzek AM, McFadden J. 2011. Differential producibility analysis (DPA) of transcriptomic data with metabolic networks: Deconstructing the metabolic response of M. tuberculosis. PLoS Comput Biol 7: e1002060.
20. Boshoff HI, Barry CE 3rd. 2005. Tuberculosis—Metabolism and respiration in the absence of growth. Nat Rev Microbiol 3: 70–80.
21. Boshoff HI, Lun DS. 2010. Systems biology approaches to understanding mycobacterial survival mechanisms. Drug Discov Today Dis Mech 7: e75–e82.
22. 1-type ATPases mediate resistance to zinc poisoning in human macrophages. Cell Host Microbe 10: 248–259.
23. Brinster S, Lamberet G, Staels B, Trieu-Cuot P, Gruss A, Poyart C. 2009. Type II fatty acid synthesis is not a suitable antibiotic target for Gram-positive pathogens. Nature 458: 83–86.
24. Brodin P, Poquet Y, Levillain F, Peguillet I, Larrouy-Maumus G, Gilleron M, Ewann F, Christophe T, Fenistein D, Jang J, et al. 2010. High content phenotypic cell-based visual screen identifies Mycobacterium tuberculosis acyltrehalose-containing glycolipids involved in phagosome remodeling. PLoS Pathog 6: e1001100.
25. Bryk R, Gold B, Venugopal A, Singh J, Samy R, Pupek K, Cao H, Popescu C, Gurney M, Hotha S, et al. 2008. Selective killing of nonreplicating mycobacteria. Cell Host Microbe 3: 137–145.
26. Bryk R, Arango N, Maksymiuk C, Balakrishnan A, Wu YT, Wong CH, Masquelin T, Hipskind P, Lima CD, Nathan C. 2013. Lipoamide channel-binding sulfonamides selectively inhibit mycobacterial lipoamide dehydrogenase. Biochemistry 52: 9375–9384.
27. Casali N, Nikolayevskyy V, Balabanova Y, Harris SR, Ignatyeva O, Kontsevaya I, Corander J, Bryant J, Parkhill J, Nejentsev S, et al. 2014. Evolution and transmission of drug-resistant tuberculosis in a Russian population. Nat Genet 46: 279–286.
28. Chakraborty S, Gruber T, Barry CE 3rd, Boshoff HI, Rhee KY. 2013. Para-aminosalicylic acid acts as an alternative substrate of folate metabolism in Mycobacterium tuberculosis. Science 339: 88–91.
29. Chambers MA, Williams A, Gavier-Widen D, Whelan A, Hall G, Marsh PD, Bloom BR, Jacobs WR, Hewinson RG. 2000. Identification of a Mycobacterium bovis BCG auxotrophic mutant that protects guinea pigs against M. bovis and hematogenous spread of Mycobacterium tuberculosis without sensitization to tuberculin. Infect Immun 68: 7094–7099.
30. Cho SH, Warit S, Wan B, Hwang CH, Pauli GF, Franzblau SG. 2007. Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother 51: 1380–1385.
31. 0 epimerase as a target for intracellular antimycobacterial inhibitors. PLoS Pathog 5: e1000645.
32. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, Gordon SV, Eiglmeier K, Gas S, Barry CE 3rd, et al. 1998. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393: 537–544.
33. Comas I, Chakravartti J, Small PM, Galagan J, Niemann S, Kremer K, Ernst JD, Gagneux S. 2010. Human T cell epitopes of Mycobacterium tuberculosis are evolutionarily hyperconserved. Nat Genet 42: 498–503.
34. Comas I, Coscolla M, Luo T, Borrell S, Holt KE, Kato-Maeda M, Parkhill J, Malla B, Berg S, Thwaites G, et al. 2013. Out-of-Africa migration and Neolithic coexpansion of Mycobacterium tuberculosis with modern humans. Nat Genet 45: 1176–1182.
35. Daniel J, Maamar H, Deb C, Sirakova TD, Kolattukudy PE. 2011. Mycobacterium tuberculosis uses host triacylglycerol to accumulate lipid droplets and acquires a dormancylike phenotype in lipid-loaded macrophages. PLoS Pathog 7: e1002093.
36. Dartois V. 2014. The path of anti-tuberculosis drugs: From blood to lesions to mycobacterial cells. Nat Rev Microbiol 12: 159–167.
37. Dartois V, Barry CE 3rd. 2013. A medicinal chemists’ guide to the unique difficulties of lead optimization for tuberculosis. Bioorg Med Chem Lett 23: 4741–4750.
38. de Carvalho LP, Lin G, Jiang X, Nathan C. 2009. Nitazoxanide kills replicating and nonreplicating Mycobacterium tuberculosis and evades resistance. J Med Chem 52: 5789– 5792.
39. de Carvalho LP, Fischer SM, Marrero J, Nathan C, Ehrt S, Rhee KY. 2010a. Metabolomics of Mycobacterium tuberculosis reveals compartmentalized co-catabolism of carbon substrates. Chem Biol 17: 1122–1131.
40. de Carvalho LP, Zhao H, Dickinson CE, Arango NM, Lima CD, Fischer SM, Ouerfelli O, Nathan C, Rhee KY. 2010b. Activity-based metabolomic profiling of enzymatic function: Identification of Rv1248c as a mycobacterial 2-hydroxy-3-oxoadipate synthase. Chem Biol 17: 323–332.
41. de Carvalho LP, Darby CM, Rhee K., Nathan C. 2011. Nitazoxanide disrupts membrane potential and intrabacterial pH homeostasis of Mycobacterium tuberculosis. ACS Med Chem Lett 2: 849–854.
42. Domenech P, Kolly GS, Leon-Solis L, Fallow A, Reed MB. 2010. Massive gene duplication event among clinical isolates of the Mycobacterium tuberculosis W/Beijing family. J Bacteriol 192: 4562–4570.
43. du Preez I, Loots D. 2012. Altered fatty acid metabolism due to rifampicin-resistance conferring mutations in the rpoB gene of Mycobacterium tuberculosis: Mapping the potential of pharmaco-metabolomics for global health and personalized medicine. Omics 16: 596–603.
44. du Preez I, Loots DT. 2013. New sputum metabolite markers implicating adaptations of the host to Mycobacterium tuberculosis, and vice versa. Tuberculosis (Edinb) 93: 330–337.
45. Duckworth BP, Geders TW, Tiwari D, Boshoff HI, Sibbald PA, Barry CE 3rd, Schnappinger D, Finzel BC, Aldrich CC. 2011. Bisubstrate adenylation inhibitors of biotin protein ligase from Mycobacterium tuberculosis. Chem Biol 18: 1432–1441.
46. Ehrt S, Guo XV, Hickey CM, Ryou M, Monteleone M, Riley LW, Schnappinger D. 2005. Controlling gene expression in mycobacteria with anhydrotetracycline and Tet repressor. Nucleic Acids Res 33: e21.
47. Eoh H, Rhee KY. 2013. Multifunctional essentiality of succinate metabolism in adaptation to hypoxia in Mycobacterium tuberculosis. Proc Natl Acad Sci 110: 6554–6559.
48. Ernst JD. 2012. The immunological life cycle of tuberculosis. Nat Rev Immunol 12: 581–591.
49. Esquerre T, Laguerre S, Turlan C, Carpousis AJ, Girbal L, Cocaign-Bousquet M. 2013. Dual role of transcription and transcript stability in the regulation of gene expression in Escherichia coli cells cultured on glucose at different growth rates. Nucleic Acids Res 42: 2460–2472.
50. Eum SY, Kong JH, Hong MS, Lee YJ, Kim JH, Hwang SH, Cho SN, Via LE, Barry CE 3rd. 2010. Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary TB. Chest 137: 122–128.
51. Farhat MR, Shapiro BJ, Kieser K, Sultana R, Jacobson KR, Victor TC, Warren RM, Streicher EM, Calver A, Sloutsky A, et al. 2013. Genomic analysis identifies targets of convergent positive selection in drug resistant Mycobacterium tuberculosis. Nat Genet 45: 1183–1189.
52. Ford CB, Lin PL, Chase MR, Shah RR, Iartchouk O, Galagan J, Mohaideen N, Ioerger TR, Sacchettini JC, Lipsitch M, et al. 2011. Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection. Nat Genet 43: 482–486.
53. Ford C, Yusim K, Ioerger T, Feng S, Chase M, Greene M, Korber B, Fortune S. 2012. Mycobacterium tuberculosis— Heterogeneity revealed through whole genome sequencing. Tuberculosis (Edinb) 92: 194–201.
54. Franzblau SG, DeGroote MA, Cho SH, Andries K, Nuermberger E, Orme IM, Mdluli K, Angulo-Barturen I, Dick T, Dartois V, et al. 2012. Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis. Tuberculosis (Edinb) 92: 453–488.
55. Galagan JE, Minch K, Peterson M, Lyubetskaya A, Azizi E, Sweet L, Gomes A, Rustad T, Dolganov G, Glotova I, et al. 2013. The Mycobacterium tuberculosis regulatory network and hypoxia. Nature 499: 178–183.
56. Garton NJ, Waddell SJ, Sherratt AL, Lee SM, Smith RJ, Senner C, Hinds J, Rajakumar K, Adegbola RA, Besra GS, et al. 2008. Cytological and transcript analyses reveal fat and lazy persister-like bacilli in tuberculous sputum. PLoS Med 5: e75.
57. Gill WP, Harik NS, Whiddon MR, Liao RP, Mittler JE, Sherman DR. 2009. A replication clock for Mycobacterium tuberculosis. Nat Med 15: 211–214.
58. Golby P, Nunez J, Witney A, Hinds J, Quail MA, Bentley S, Harris S, Smith N, Hewinson RG, Gordon SV. 2013. Genome-level analyses of Mycobacterium bovis lineages reveal the role of SNPs and antisense transcription in differential gene expression. BMC Genomics 14: 710.
59. Gold B, Pingle M, Brickner SJ, Shah N, Roberts J, Rundell M, Bracken WC, Warrier T, Somersan S, Venugopal A, et al. 2012. Nonsteroidal anti-inflammatory drug sensitizes Mycobacterium tuberculosis to endogenous and exogenous antimicrobials. Proc Natl Acad Sci 109: 16004– 16011.
60. Goldman RC. 2013. Why are membrane targets discovered by phenotypic screens and genome sequencing in Mycobacterium tuberculosis? Tuberculosis (Edinb) 93: 569–588.
61. 12 metabolism in Mycobacterium tuberculosis. Future Microbiol 8: 1405–1418.
62. 12 transporter in Mycobacterium tuberculosis. Open Biol 3: 120175.
63. Gordhan BG, Smith DA, Alderton H, McAdam RA, Bancroft GJ, Mizrahi V. 2002. Construction and phenotypic characterization of an auxotrophic mutant of Mycobacterium tuberculosis defective in L-arginine biosynthesis. Infect Immun 70: 3080–3084.
64. Gouzy A, Larrouy-Maumus G, Wu TD, Peixoto A, Levillain F, Lugo-Villarino G, Gerquin-Kern JL, de Carvalho LP, Poquet Y, Neyrolles O. 2013. Mycobacterium tuberculosis nitrogen assimilation and host colonization require aspartate. Nat Chem Biol 9: 674–676.
65. Gouzy A, Larrouy-Maumus G, Bottai D, Levillain F, Dumas A, Wallach JB, Caire-Brandli I, de Chastellier C, Wu TD, Poincloux R, et al. 2014. Mycobacterium tuberculosis exploits asparagine to assimilate nitrogen and resist acid stress during Infection. PLoS Pathog 10: e1003928.
66. Grant SS, Kawate T, Nag PP, Silvis MR, Gordon K, Stanley SA, Kazyanskaya E, Nietupski R, Golas A, Fitzgerald M, et al. 2013. Identification of novel inhibitors of nonreplicating Mycobacterium tuberculosis using a carbon starvation model. ACS Chem Biol 8: 2224–2234.
67. Griffin JE, Gawronski JD, Dejesus MA, Ioerger TR, Akerley BJ, Sassetti CM. 2011. High-resolution phenotypic profiling defines genes essential for mycobacterial growth and cholesterol catabolism. PLoS Pathog 7: e1002251.
68. Griffin JE, Pandey AK, Gilmore SA, Mizrahi V, McKinney JD, Bertozzi CR, Sassetti CM. 2012. Cholesterol catabolism by Mycobacterium tuberculosis requires transcriptional and metabolic adaptations. Chem Biol 19: 218– 227.
69. Halouska S, Fenton RJ, Barletta RG, Powers R. 2012. Predicting the in vivo mechanism of action for drug leads using NMR metabolomics. ACS Chem Biol 7: 166–171.
70. Halouska S, Fenton RJ, Zinniel DK, Marshall DD, Barletta RG, Powers R. 2013. Metabolomics analysis identifies D-alanine-D-alanine ligase as the primary lethal target of D-cycloserine in mycobacteria. J Proteome Res 13: 1065–1076.
71. Hawn TR, Matheson AI, Maley SN, Vandal O. 2013. Hostdirected therapeutics for tuberculosis: Can we harness the host? Microbiol Mol Biol Rev 77: 608–627.
72. Hernandez-Pando R, Jeyanathan M, Mengistu G, Aguilar D, Orozco H, Harboe M, Rook GA, Bjune G. 2000. Persistence of DNA from Mycobacterium tuberculosis in superficially normal lung tissue during latent infection. Lancet 356: 2133–2138.
73. Hingley-Wilson SM, Sambandamurthy VK, Jacobs WR Jr., 2003. Survival perspectives from the world’s most successful pathogen, Mycobacterium tuberculosis. Nat Immunol 4: 949–955.
74. Hinshelwood S, Stoker NG. 1992. Cloning of mycobacterial histidine synthesis genes by complementation of a Myco bacterium smegmatis auxotroph. Mol Microbiol 6: 2887– 2895.
75. Hu Y, Movahedzadeh F, Stoker NG, Coates AR. 2006. Deletion of the Mycobacterium tuberculosis a-crystallin-like hspX gene causes increased bacterial growth in vivo. Infect Immun 74: 861–868.
76. Ishii N, Nakahigashi K, Baba T, Robert M, Soga T, Kanai A, Hirasawa T, Naba M, Hirai K, Hoque A, et al. 2007. Multiple high-throughput analyses monitor the response of E. coli to perturbations. Science 316: 593–597.
77. Jackson M. 2014. The mycobacterial cell envelope—Lipids. Cold Spring Harb Perspect Med 4: a021105.
78. Jackson M, Stadthagen G, Gicquel B. 2007. Long-chain multiple methyl-branched fatty acid-containing lipids of Mycobacterium tuberculosis: Biosynthesis, transport, regulation and biological activities. Tuberculosis (Edinb) 87: 78–86.
79. Jain M, Petzold CJ, Schelle MW, Leavell MD, Mougous JD, Bertozzi CR, Leary JA, Cox JS. 2007. Lipidomics reveals control of Mycobacterium tuberculosis virulence lipids via metabolic coupling. Proc Natl Acad Sci 104: 5133– 5138.
80. Jayaswal S, Kamal MA, Dua R, Gupta S, Majumdar T, Das G, Kumar D, Rao KV. 2010. Identification of host-dependent survival factors for intracellular Mycobacterium tuberculosis through an siRNA screen. PLoS Pathog 6: e1000839.
81. Kalscheuer R, Weinrick B, Veeraraghavan U, Besra GS, Jacobs WR Jr., 2010. Trehalose-recycling ABC transporter LpqY-SugA-SugB-SugC is essential for virulence of Mycobacterium tuberculosis. Proc Natl Acad Sci 107: 21761– 21766.
82. Kaplan G, Post FA, Moreira AL, Wainwright H, Kreiswirth BN, Tanverdi M, Mathema B, Ramaswamy SV, Walther G, Steyn LM, et al. 2003. Mycobacterium tuberculosis growth at the cavity surface: A microenvironment with failed immunity. Infect Immun 71: 7099–7108.
83. Karakousis PC, Williams EP, Bishai WR. 2008. Altered expression of isoniazid-regulated genes in drug-treated dormant Mycobacterium tuberculosis. J Antimicrob Chemother 61: 323–331.
84. Keating LA, Wheeler PR, Mansoor H, Inwald JK, Dale J, Hewinson RG, Gordon SV. 2005. The pyruvate requirement of some members of the Mycobacterium tuberculosis complex is due to an inactive pyruvate kinase: Implications for in vivo growth. Mol Microbiol 56: 163–174.
85. Khatri B, Fielder M, Jones G, Newell W, Abu-Oun M, Wheeler PR. 2013. High throughput phenotypic analysis of Mycobacterium tuberculosis and Mycobacterium bovis strains’ metabolism using biolog phenotype microarrays. PLoS ONE 8: e52673.
86. Kim MJ, Wainwright HC, Locketz M, Bekker LG, Walther GB, Dittrich C, Visser A, Wang W, Hsu FF, Wiehart U, et al. 2010. Caseation of human tuberculosis granulomas correlates with elevated host lipid metabolism. EMBO Mol Med 2: 258–274.
87. Kim JH, O’Brien KM, Sharma R, Boshoff HI, Rehren G, Chakraborty S, Wallach JB, Monteleone M, Wilson DJ, Aldrich CC, et al. 2013. A genetic strategy to identify targets for the development of drugs that prevent bacterial persistence. Proc Natl Acad Sci 110: 19095–19100.
88. Kjer-Nielsen L, Patel O, Corbett AJ, Le Nours J, Meehan B, Liu L, Bhati M, Chen Z, Kostenko L, Reantragoon R, et al. 2012. MR1 presents microbial vitamin B metabolites to MAIT cells. Nature 491: 717–723.
89. Koch A, Mizrahi V, Warner DF. 2014. The impact of drug resistance on Mycobacterium tuberculosis physiology: What can we learn from rifampicin? Emerg Microb Infect 3: e17.
90. Kolly GS, Boldrin F, Sala C, Dhar N, Hartkoorn RC, Ventura M, Serafini A, McKinney JD, Manganelli R, Cole ST. 2014. Assessing the essentiality of the decaprenyl-phospho-Darabinofuranose pathway in Mycobacterium tuberculosis using conditional mutants. Mol Microbiol 92: 194–211.
91. Koul A, Vranckx L, Dhar N, Gohlmann HW, Ozdemir E, Neefs JM, Schulz M, Lu P, Mortz E, McKinney JD, et al. 2014. Delayed bactericidal response of Mycobacterium tuberculosis to bedaquiline involves remodelling of bacterial metabolism. Nat Commun 5: 3369.
92. Kumar D, Rao KV. 2011. Regulation between survival, persistence, and elimination of intracellular mycobacteria: A nested equilibrium of delicate balances. Microbes Infect 13: 121–133.
93. Kumar D, Nath L, Kamal MA, Varshney A, Jain A, Singh S, Rao KV. 2010. Genome-wide analysis of the host intracellular network that regulates survival of Mycobacterium tuberculosis. Cell 140: 731–743.
94. Kumar B, Sharma D, Sharma P, Katoch VM, Venkatesan K, Bisht D. 2013. Proteomic analysis of Mycobacterium tuberculosis isolates resistant to kanamycin and amikacin. J Proteomics 94: 68–77.
95. Larrouy-Maumus G, Biswas T, Hunt DM, Kelly G, Tsodikov OV, de Carvalho LP. 2013. Discovery of a glycerol 3-phosphate phosphatase reveals glycerophospholipid polar head recycling in Mycobacterium tuberculosis. Proc Natl Acad Sci 110: 11320–11325.
96. Larsen MH, Biermann K, Chen B, Hsu T, Sambandamurthy VK, Lackner AA, Aye PP, Didier P, Huang D, Shao L, et al. 2009. Efficacy and safety of live attenuated persistent and rapidly cleared Mycobacterium tuberculosis vaccine candidates in non-human primates. Vaccine 27: 4709–4717.
97. Lechartier B, Rybniker J, Zumla A, Cole ST. 2014. Tuberculosis drug discovery in the post-post-genomic era. EMBO Mol Med 6: 158–168.
98. Lee W, VanderVen BC, Fahey RJ, Russell DG. 2013. Intracellular Mycobacterium tuberculosis exploits host-derived fatty acids to limit metabolic stress. J Biol Chem 288: 6788–6800.
99. Lew JM, Mao C, Shukla M, Warren A, Will R, Kuznetsov D, Xenarios I, Robertson BD, Gordon SV, Schnappinger D, et al. 2013. Database resources for the tuberculosis community. Tuberculosis (Edinb) 93: 12–17.
100. Li SK, Ng PK, Qin H, Lau JK, Lau JP, Tsui SK, Chan TF, Lau TC. 2013. Identification of small RNAs in Mycobacterium smegmatis using heterologous Hfq. RNA 19: 74–84.
101. Lin PL, Rodgers M, Smith L, Bigbee M, Myers A, Bigbee C, Chiosea I, Capuano SV, Fuhrman C, Klein E, et al. 2009. Quantitative comparison of active and latent tuberculosis in the cynomolgus macaque model. Infect Immun 77: 4631–4642.
102. Lin PL, Ford CB, Coleman MT, Myers AJ, Gawande R, Ioerger T, Sacchettini J, Fortune S., Flynn JL. 2013. Sterilization of granulomas is common in active and latent tuberculosis despite within-host variability in bacterial killing. Nat Med 20: 75–79.
103. Lofthouse EK, Wheeler PR, Beste DJ, Khatri BL, Wu H, Mendum TA, Kierzek AM, McFadden J. 2013. Systemsbased approaches to probing metabolic variation within the Mycobacterium tuberculosis complex. PLoS ONE 8: e75913.
104. Loots DT. 2014. An altered Mycobacterium tuberculosis metabolome induced by katG mutations resulting in isoniazid resistance. Antimicrob Agents Chemother 58: 2144–2149.
105. Lowe DM, Redford PS, Wilkinson RJ, O’Garra A, Martineau AR. 2012. Neutrophils in tuberculosis: Friend or foe? Trends Immunol 33: 14–25.
106. Mahapatra S, Hess AM, Johnson JL, Eisenach KD, DeGroote MA, Gitta P, Joloba ML, Kaplan G, Walzl G, Boom WH, et al. 2014. A metabolic biosignature of early response to anti-tuberculosis treatment. BMC Infect Dis 14: 53.
107. Marrero J, Rhee K., Schnappinger D, Pethe K, Ehrt S. 2010. Gluconeogenic carbon flow of tricarboxylic acid cycle intermediates is critical for Mycobacterium tuberculosis to establish and maintain infection. Proc Natl Acad Sci 107: 9819–9824.
108. Marrero J, Trujillo C, Rhee K., Ehrt S. 2013. Glucose phosphorylation is required for Mycobacterium tuberculosis persistence in mice. PLoS Pathog 9: e1003116.
109. Mattila JT, Ojo OO, Kepka-Lenhart D, Marino S, Kim JH, Eum SY, Via LE, Barry CE 3rd, Klein E, Kirschner DE, et al. 2013. Microenvironments in tuberculous granulomas are delineated by distinct populations of macrophage subsets and expression of nitric oxide synthase and arginase isoforms. J Immunol 191: 773–784.
110. McAdam RA, Weisbrod TR, Martin J, Scuderi JD, Brown AM, Cirillo JD, Bloom BR, Jacobs WR Jr., 1995. In vivo growth characteristics of leucine and methionine auxotrophic mutants of Mycobacterium bovis BCG generated by transposon mutagenesis. Infect Immun 63: 1004– 1012.
111. McGuire AM, Weiner B, Park ST, Wapinski I, Raman S, Dolganov G, Peterson M, Riley R, Zucker J, Abeel T, et al. 2012. Comparative analysis of mycobacterium and related actinomycetes yields insight into the evolution of Mycobacterium tuberculosis pathogenesis. BMC Genomics 13: 120.
112. McKinney JD, Honer zu Bentrup K, Munoz-Elias EJ, Miczak A, Chen B, Chan WT, Swenson D, Sacchettini JC, Jacobs WR Jr., Russell DG. 2000. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature 406: 735–738.
113. Michelucci A, Cordes T, Ghelfi J, Pailot A, Reiling N, Goldmann O, Binz T, Wegner A, Tallam A, Rausell A, et al. 2013. Immune-responsive gene 1 protein links metabolism to immunity by catalyzing itaconic acid production. Proc Natl Acad Sci 110: 7820–7825.
114. Molle V, Kremer L. 2010. Division and cell envelope regulation by Ser/Thr phosphorylation: Mycobacterium shows the way. Mol Microbiol 75: 1064–1077.
115. Munoz-Elias EJ, McKinney JD. 2005. Mycobacterium tuberculosis isocitrate lyases 1 and 2 are jointly required for in vivo growth and virulence. Nat Med 11: 638–644.
116. Munoz-Elias EJ, McKinney JD. 2006. Carbon metabolism of intracellular bacteria. Cell Microbiol 8: 10–22.
117. Munoz-Elias EJ, Upton AM, Cherian J, McKinney JD. 2006. Role of the methylcitrate cycle in Mycobacterium tuberculosis metabolism, intracellular growth, and virulence. Mol Microbiol 60: 1109–1122.
118. O’Garra A, Redford PS, McNab FW, Bloom CI, Wilkinson RJ, Berry MP. 2013. The immune response in tuberculosis. Annu Rev Immunol 31: 475–527.
119. Olivier I, Loots D. 2012. A metabolomics approach to characterise and identify various Mycobacterium species. J Microbiol Methods 88: 419–426.
120. Owens CP, Chim N, Graves AB, Harmston CA, Iniguez A, Contreras H, Liptak MD, Goulding CW. 2013. The Mycobacterium tuberculosis secreted protein Rv0203 transfers heme to membrane proteins MmpL3 and MmpL11. J Biol Chem 288: 21714–21728.
121. Pandey AK, Sassetti CM. 2008. Mycobacterial persistence requires the utilization of host cholesterol. Proc Natl Acad Sci 105: 4376–4380.
122. Parish T. 2003. Starvation survival response of Mycobacterium tuberculosis. J Bacteriol 185: 6702–6706.
123. Parish T, Smith DA, Kendall S, Casali N, Bancroft GJ, Stoker NG. 2003. Deletion of two-component regulatory systems increases the virulence of Mycobacterium tuberculosis. Infect Immun 71: 1134–1140.
124. Pavelka MS Jr., Chen B, Kelley CL, Collins FM, Jacobs WR Jr., 2003. Vaccine efficacy of a lysine auxotroph of Mycobacterium tuberculosis. Infect Immun 71: 4190–4192.
125. Pethe K, Sequeira PC, Agarwalla S, Rhee K, Kuhen K, Phong WY, Patel V, Beer D, Walker JR, Duraiswamy J, et al. 2010. A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy. Nat Commun 1: 57.
126. Peyron P, Vaubourgeix J, Poquet Y, Levillain F, Botanch C, Bardou F, Daffe M, Emile JF, Marchou B, Cardona PJ, et al. 2008. Foamy macrophages from tuberculous patients’ granulomas constitute a nutrient-rich reservoir for M. tuberculosis persistence. PLoS Pathog 4: e1000204.
127. Prosser GA, de Carvalho LP. 2013. Metabolomics reveal D-alanine: D-alanine ligase as the target of D-cycloserine in Mycobacterium tuberculosis. ACS Med Chem Lett 4: 1233–1237.
128. Qualls JE, Subramanian C, Rafi W, Smith AM, Balouzian L, DeFreitas AA, Shirey KA, Reutterer B, Kernbauer E, Stockinger S, et al. 2012. Sustained generation of nitric oxide and control of mycobacterial infection requires argininosuccinate synthase 1. Cell Host Microbe 12: 313–323.
129. Rengarajan J, Bloom BR, Rubin EJ. 2005. Genome-wide requirements for Mycobacterium tuberculosis adaptation and survival in macrophages. Proc Natl Acad Sci 102: 8327–8332.
130. Rhee K. 2013. Minding the gaps: Metabolomics mends functional genomics. EMBO Rep 14: 949–950.
131. Rhee K., de Carvalho LP., Bryk R, Ehrt S, Marrero J, Park SW, Schnappinger D, Venugopal A, Nathan C. 2011. Central carbon metabolism in Mycobacterium tuberculosis: An unexpected frontier. Trends Microbiol 19: 307–314.
132. Rohde KH, Veiga DF, Caldwell S, Balazsi G, Russell DG. 2012. Linking the transcriptional profiles and the physiological states of Mycobacterium tuberculosis during an extended intracellular infection. PLoS Pathog 8: e1002769.
133. Rose G, Cortes T, Comas I, Coscolla M, Gagneux S, Young DB. 2013. Mapping of genotype-phenotype diversity among clinical isolates of Mycobacterium tuberculosis by sequence-based transcriptional profiling. Genome Biol Evol 5: 1849–1862.
134. Russell DG. 2011. Mycobacterium tuberculosis and the intimate discourse of a chronic infection. Immunol Rev 240: 252–268.
135. Rustad TR, Minch KJ, Brabant W, Winkler JK, Reiss DJ, Baliga NS, Sherman DR. 2013. Global analysis of mRNA stability in Mycobacterium tuberculosis. Nucleic Acids Res 41: 509–517.
136. Sambandamurthy VK, Derrick SC, Jalapathy KV, Chen B, Russell RG, Morris SL, Jacobs WR Jr, 2005. Long-term protection against tuberculosis following vaccination with a severely attenuated double lysine and pantothenate auxotroph of Mycobacterium tuberculosis. Infect Immun 73: 1196–1203.
137. Sampson SL, Dascher CC, Sambandamurthy VK, Russell RG, Jacobs WR Jr, Bloom BR, Hondalus MK. 2004. Protection elicited by a double leucine and pantothenate auxotroph of Mycobacterium tuberculosis in guinea pigs. Infect Immun 72: 3031–3037.
138. Sampson SL, Mansfield KG, Carville A, Magee DM, Quitugua T, Howerth EW, Bloom BR, Hondalus MK. 2011. Extended safety and efficacy studies of a live attenuated double leucine and pantothenate auxotroph of Mycobacterium tuberculosis as a vaccine candidate. Vaccine 29: 4839–4847.
139. Sassetti CM, Rubin EJ. 2003. Genetic requirements for mycobacterial survival during infection. Proc Natl Acad Sci 100: 12989–12994.
140. Sassetti CM, Boyd DH, Rubin EJ. 2003. Genes required for mycobacterial growth defined by high density mutagenesis. Mol Microbiol 48: 77–84.
141. 12-dependent methylmalonyl pathway in Mycobacterium tuberculosis: Implications for propionate metabolism during growth on fatty acids. J Bacteriol 190: 3886–3895.
142. Schnappinger D, Ehrt S, Voskuil MI, Liu Y, Mangan JA, Monahan IM, Dolganov G, Efron B, Butcher PD, Nathan C, et al. 2003. Transcriptional adaptation of Mycobacterium tuberculosis within macrophages: Insights into the phagosomal environment. J Exp Med 198: 693–704.
143. Schwegmann A, Brombacher F. 2008. Host-directed drug targeting of factors hijacked by pathogens. Sci Signal 1: re8.
144. Schwenk A, Macallan DC. 2000. Tuberculosis, malnutrition and wasting. Curr Opin Clin Nutr Metab Care 3: 285– 291.
145. Shi S, Ehrt S. 2006. Dihydrolipoamide acyltransferase is critical for Mycobacterium tuberculosis pathogenesis. Infect Immun 74: 56–63.
146. Shi C, Geders TW, Park SW, Wilson DJ, Boshoff HI, Abayomi O, Barry CE 3rd, Schnappinger D, Finzel BC, Aldrich CC. 2011. Mechanism-based inactivation by aromatization of the transaminase BioA involved in biotin biosynthesis in Mycobaterium tuberculosis. J Am Chem Soc 133: 18194–18201.
147. Shimono N, Morici L, Casali N, Cantrell S, Sidders B, Ehrt S, Riley LW. 2003. Hypervirulent mutant of Mycobacterium tuberculosis resulting from disruption of the mce1 operon. Proc Natl Acad Sci 100: 15918–15923.
148. 1H NMR-based metabolomic profiling in mice infected with Mycobacterium tuberculosis. J Proteome Res 10: 2238–2247.
149. Shitikov EA, Bespyatykh JA, Ischenko DS, Alexeev DG, Karpova IY, Kostryukova ES, Isaeva YD, Nosova EY, Mokrousov IV, Vyazovaya AA, et al. 2014. Unusual large-scale chromosomal rearrangements in Mycobacterium tuberculosis Beijing B0/W148 cluster isolates. PLoS ONE 9: e84971.
150. Singh V, Jamwal S, Jain R, Verma P, Gokhale R, Rao KV. 2012. Mycobacterium tuberculosis-driven targeted recalibration of macrophage lipid homeostasis promotes the foamy phenotype. Cell Host Microbe 12: 669–681.
151. Slayden RA, Jackson M, Zucker J, Ramirez MV, Dawson CC, Crew R, Sampson NS, Thomas ST, Jamshidi N, Sisk P, et al. 2013. Updating and curating metabolic pathways of TB. Tuberculosis (Edinb) 93: 47–59.
152. Smith DA, Parish T, Stoker NG, Bancroft GJ. 2001. Characterization of auxotrophic mutants of Mycobacterium tuberculosis and their potential as vaccine candidates. Infect Immun 69: 1142–1150.
153. reg cell homeostasis. Science 341: 569–573.
154. Somashekar BS, Amin AG, Tripathi P, MacKinnon N, Rithner CD, Shanley CA, Basaraba R, Henao-Tamayo M, Kato-Maeda M, Ramamoorthy A, et al. 2012. Metabolomic signatures in guinea pigs infected with epidemicassociated W-Beijing strains of Mycobacterium tuberculosis. J Proteome Res 11: 4873–4884.
155. Stanley SA, Barczak AK, Silvis MR, Luo SS, Sogi K, Vokes M, Bray MA, Carpenter AE, Moore CB, Siddiqi N, et al. 2014. Identification of host-targeted small molecules that restrict intracellular Mycobacterium tuberculosis growth. PLoS Pathog 10: e1003946.
156. Stinear TP, Seemann T, Harrison PF, Jenkin GA, Davies JK, Johnson PD, Abdellah Z, Arrowsmith C, Chillingworth T, Churcher C, et al. 2008. Insights from the complete genome sequence of Mycobacterium marinum on the evolution of Mycobacterium tuberculosis. Genome Res 18: 729–741.
157. Strelko CL, Lu W, Dufort FJ, Seyfried TN, Chiles TC, Rabinowitz JD, Roberts MF. 2011. Itaconic acid is a mammalian metabolite induced during macrophage activation. J Am Chem Soc 133: 16386–16389.
158. Supply P, Marceau M, Mangenot S, Roche D, Rouanet C, Khanna V, Majlessi L, Criscuolo A, Tap J, Pawlik A, et al. 2013. Genomic analysis of smooth tubercle bacilli provides insights into ancestry and pathoadaptation of Mycobacterium tuberculosis. Nat Genet 45: 172–179.
159. Tannahill GM, Curtis AM, Adamik J, Palsson-McDermott EM, McGettrick AF, Goel G, Frezza C, Bernard NJ, Kelly B, Foley NH, et al. 2013. Succinate is an inflammatory signal that induces IL-1b through HIF-1a. Nature 496: 238–242.
160. Thomas ST, VanderVen BC, Sherman DR, Russell DG, Sampson NS. 2011. Pathway profiling in Mycobacterium tuberculosis: Elucidation of cholesterol-derived catabolite and enzymes that catalyze its metabolism. J Biol Chem 286: 43668–43678.
161. Tian J, Bryk R, Itoh M, Suematsu M, Nathan C. 2005a. Variant tricarboxylic acid cycle in Mycobacterium tuberculosis: Identification of a-ketoglutarate decarboxylase. Proc Natl Acad Sci 102: 10670–10675.
162. Tian J, Bryk R, Shi S, Erdjument-Bromage H, Tempst P, Nathan C. 2005b. Mycobacterium tuberculosis appears to lack a-ketoglutarate dehydrogenase and encodes pyruvate dehydrogenase in widely separated genes. Mol Microbiol 57: 859–868.
163. Timm J, Post FA, Bekker LG, Walther GB, Wainwright HC, Manganelli R, Chan WT, Tsenova L, Gold B, Smith I, et al. 2003. Differential expression of iron-, carbon-, and oxygen-responsive mycobacterial genes in the lungs of chronically infected mice and tuberculosis patients. Proc Natl Acad Sci 100: 14321–14326.
164. Tsolaki AG, Hirsh AE, DeRiemer K, Enciso JA, Wong MZ, Hannan M, Goguet de la Salmoniere YO, Aman K, KatoMaeda M, Small PM. 2004. Functional and evolutionary genomics of Mycobacterium tuberculosis: Insights from genomic deletions in 100 strains. Proc Natl Acad Sci 101: 4865–4870.
165. Tullius MV, Harmston CA, Owens CP, Chim N, Morse RP, McMath LM, Iniguez A, Kimmey JM, Sawaya MR, Whitelegge JP, et al. 2011. Discovery and characterization of a unique mycobacterial heme acquisition system. Proc Natl Acad Sci 108: 5051–5056.
166. Uhía I, Williams KJ, Shahrezaei V, Robertson BD. 2014. Mycobacterial growth. Cold Spring Harb Perspect Med doi: 10.1101/cshperspect.a021097.
167. Vandal O., Pierini LM, Schnappinger D, Nathan C., Ehrt S. 2008. A membrane protein preserves intrabacterial pH in intraphagosomal Mycobacterium tuberculosis. Nat Med 14: 849–854.
168. Ventura M, Rieck B, Boldrin F, Degiacomi G, Bellinzoni M, Barilone N, Alzaidi F, Alzari PM, Manganelli R, O’Hare HM. 2013. GarA is an essential regulator of metabolism in Mycobacterium tuberculosis. Mol Microbiol 90: 356– 366.
169. Venugopal A, Bryk R, Shi S, Rhee K, Rath P, Schnappinger D, Ehrt S, Nathan C. 2011. Virulence of Mycobacterium tuberculosis depends on lipoamide dehydrogenase, a member of three multienzyme complexes. Cell Host Microbe 9: 21–31.
170. Via LE, Lin PL, Ray SM, Carrillo J, Allen SS, Eum SY, Taylor K, Klein E, Manjunatha U, Gonzales J, et al. 2008. Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. Infect Immun 76: 2333–2340.
171. Via LE, Weiner DM, Schimel D, Lin PL, Dayao E, Tankersley SL, Cai Y, Coleman MT, Tomko J, Paripati P, et al. 2013. Differential virulence and disease progression following Mycobacterium tuberculosis complex infection of the common marmoset (Callithrix jacchus). Infect Immun 81: 2909–2919.
172. Wagner D, Maser J, Lai B, Cai Z, Barry CE 3rd, Honer Zu Bentrup K, Russell DG, Bermudez LE. 2005. Elemental analysis of Mycobacterium avium-, Mycobacterium tuberculosis-, and Mycobacterium smegmatis-containing phag osomes indicates pathogen-induced microenvironments within the host cell’s endosomal system. J Immunol 174: 1491–1500.
173. Wagner T, Bellinzoni M, Wehenkel A, O’Hare HM, Alzari PM. 2011. Functional plasticity and allosteric regulation of a-ketoglutarate decarboxylase in central mycobacterial metabolism. Chem Biol 18: 1011–1020.
174. Warner DF, Mizrahi V. 2008. Physiology of Mycobacterium tuberculosis. InTuberculosis handbook, Vol. 1 (ed. Rubin EJ, Kaufmann SHE), pp. 53–59. Wiley-VCH, Weinheim, Germany.
175. Warner DF, Mizrahi V. 2012. Approaches to target identification and validation for tuberculosis drug discovery: A UCT perspective. S Afr Med J 102: 457–460.
176. 12-independent methionine synthase in Mycobacterium tuberculosis: Implications for differential methionine synthase function in strains H37Rv and CDC1551. J Bacteriol 189: 3655– 3659.
177. Watanabe S, Zimmermann M, Goodwin MB, Sauer U, Barry CE 3rd, Boshoff HI. 2011. Fumarate reductase activity maintains an energized membrane in anaerobic Mycobacterium tuberculosis. PLoS Pathog 7: e1002287.
178. Wei JR, Krishnamoorthy V, Murphy K, Kim JH, Schnappinger D, Alber T, Sassetti CM, Rhee K., Rubin EJ. 2011. Depletion of antibiotic targets has widely varying effects on growth. Proc Natl Acad Sci 108: 4176–4181.
179. Weiner B, Gomez J, Victor TC, Warren RM, Sloutsky A, Plikaytis BB, Posey JE, van Helden PD, Gey van Pittius NC, Koehrsen M, et al. 2012a. Independent large scale duplications in multiple M. tuberculosis lineages overlapping the same genomic region. PLoS ONE 7: e26038.
180. Weiner J 3rd, Parida SK, Maertzdorf J, Black GF, Repsilber D, Telaar A, Mohney RP, Arndt-Sullivan C, Ganoza CA, Fae KC, et al. 2012b. Biomarkers of inflammation, immunosuppression and stress with active disease are revealed by metabolomic profiling of tuberculosis patients. PLoS ONE 7: e40221.
181. Wheeler PR, Ratledge C. 1994. Metabolism of Mycobacterium tuberculosis. InTuberculosis: Pathogenesis, protection, and control (ed. Bloom BR), pp. 353–385. American Society for Microbiology, Washington, DC.
182. Williams M, Mizrahi V, Kana BD. 2014. Molybdenum cofactor: A key component of Mycobacterium tuberculosis pathogenesis? Crit Rev Microbiol 40: 18–29.
183. Wolfe LM, Veeraraghavan U, Idicula-Thomas S, Schurer S, Wennerberg K, Reynolds R, Besra GS, Dobos KM. 2013. A chemical proteomics approach to profiling the ATPbinding proteome of Mycobacterium tuberculosis. Mol Cell Proteomics 12: 1644–1660.
184. Woolhiser L, Tamayo MH, Wang B, Gruppo V, Belisle JT, Lenaerts AJ, Basaraba RJ, Orme IM. 2007. In vivo adaptation of the Wayne model of latent tuberculosis. Infect Immun 75: 2621–2625.
185. Zhang YJ, Ioerger TR, Huttenhower C, Long JE, Sassetti CM, Sacchettini JC, Rubin EJ. 2012. Global assessment of genomic regions required for growth in Mycobacterium tuberculosis. PLoS Pathog 8: e1002946.
186. Zhang H, Li D, Zhao L, Fleming J, Lin N, Wang T, Liu Z, Li C, Galwey N, Deng J, et al. 2013a. Genome sequencing of 161 Mycobacterium tuberculosis isolates from China identifies genes and intergenic regions associated with drug resistance. Nat Genet 45: 1255– 1260.
187. Zhang YJ, Reddy MC, Ioerger TR, Rothchild AC, Dartois V, Schuster BM, Trauner A, Wallis D, Galaviz S, Huttenhower C, et al. 2013b. Tryptophan biosynthesis protects mycobacteria from CD4 T-cell-mediated killing. Cell 155: 1296–1308.
188. Zheng J, Rubin EJ, Bifani P, Mathys V, Lim V, Au M, Jang J, Nam J, Dick T, Walker JR, et al. 2013. para-Aminosalicylic acid is a prodrug targeting dihydrofolate reductase in Mycobacterium tuberculosis. J Biol Chem 288: 23447– 23456.
189. 1H NMR spectroscopy-based metabolomics to sera of tuberculosis patients. J Proteome Res 12: 4642–4649.